

# LUNG CANCER CENTER

QUARTERLY EMAIL NEWSLETTER - OCTOBER 2023



## Inaugural Lung Cancer Center Newsletter

With the intent of keeping our Lung Cancer Center colleagues and collaborators informed, the Lung Cancer Center is launching a dedicated quarterly newsletter.

In this communication, we plan to include exciting new and noteworthy happenings of the Center: research, clinical, and otherwise. Moving forward, please share anything you are interested in highlighting in future newsletters with Kristen Labbe, Program Manager of the Lung Cancer Center, via email at: [Kristen.Labbe@nyulangone.org](mailto:Kristen.Labbe@nyulangone.org).

Sincerely,

A handwritten signature in black ink, appearing to read "Abraham Chachoua".

Abraham Chachoua, MD  
Lung Cancer Center Director

**Perlmutter  
Cancer Center**

### IN THIS NEWSLETTER

**Meet the LCC Leadership Team**  
PAGE 2

**Spotlight - LCC Priority Working Groups**  
PAGE 2 & 3

**Featured Clinical Trials**  
PAGE 3

**ASCO 2023 Annual Meeting Highlights**  
PAGE 4

**Announcements**  
PAGE 5

**Kwok-Kin Wong, MD, PhD**  
Basic/Translational Science



**Harvey Pass, MD**  
Thoracic Surgery



**Abraham Chachoua, MD**  
Medical Oncology  
Director, Lung Cancer Center



**Jeffrey Schneider, MD**  
Medical Oncology



# MEET THE LUNG CANCER CENTER LEADERSHIP TEAM

**Robert Cerfolio, MD, MBA**  
Thoracic Surgery



**Donna Shelley, MD**  
NYU School of Global  
Public Health




**Kristen Labbe, MPH**  
Program Manager,  
Lung Cancer Center



**Daniel Sterman, MD**  
Interventional Pulmonary



**Benjamin Cooper, MD**  
Radiation Oncology



**Vamsidhar Velcheti, MD**  
Medical Oncology



**William Moore, MD**  
Radiology



## SPOTLIGHT: LCC PRIORITY WORKING GROUPS



**DANIEL STERMAN, MD**



**JEFFREY SCHNEIDER, MD**

### Lung Cancer Screening Program

Early detection of high-risk lung cancer cases through annual low-dose computed tomography (CT) scans can reduce the lung cancer death rate by up to 20 percent. To expand access to these lifesaving scans, under the leadership of Dr. Schneider & Dr. Sterman, we have established a comprehensive Lung Cancer Screening Program, which includes several sites throughout Manhattan, Brooklyn, Queens, and Long Island. Our goal is to ensure that more patients and families have access to NYU Langone's gold standard of care through a vast, fully integrated healthcare system.

In the coming months, the Lung Cancer Screening Program aims to streamline the referral process and expand our referral base across the institution. Additionally, the Female Asian Nonsmoker Screening Study (FANSS), led by PI Dr. Shum, aims to expand recruitment and enrollment efforts. This population is at increased risk for developing lung cancer, but do not meet current lung cancer screening USPTF criteria.



**VAMSIDHAR VELCHETI, MD**

### Clinical Trials Portfolio

As the Medical Director of the Thoracic Oncology Program at PCC, Dr. Velcheti, along with the PCC Clinical Trials Office, have expanded the Thoracic clinical trial portfolio significantly over the past few years. Growing from 17 active clinical trials in 2019, to over 50 active clinical trials currently in 2023, this growth is also seen through a fivefold increase in the number of patients enrolled in clinical trials in this time period. The Thoracic DMG has also expanded their clinical presence, serving patients now at PCC - Sunset Park, with a focus on better serving the diverse population of patients in our catchment area through expanded access to care. On top of all the success and expanded clinical presence, the Thoracic DMG has also run several practice changing clinical trials, leading to FDA approval.

With an active focus on bringing in the best trials available for our patients, the LCC is actively opening cutting edge and investigator initiated trials to better serve the needs of our patient population. Some of these exciting trials are highlighted on Page 3.

# SPOTLIGHT: LCC PRIORITY WORKING GROUPS



KWOK-KIN WONG, MD, PHD



HARVEY PASS, MD

## Translational Research

Led by Dr. Wong and Dr. Pass, the Translational Research priority bridges the gap between the clinic and basic science. This priority focuses on key areas of interest for the LCC researchers and clinicians, such as screening and early detection, predicting recurrence, 'undruggable' targets such as KRAS, and areas of unmet need including Small Cell Lung Cancer (SCLC) and Lung Squamous Cell Carcinoma. Another focus of this priority is to foster scientific collaborations internally, as well as externally with neighboring institutions and beyond.

The team is in the midst of another NIH P50 Sponsored Programs of Research Excellence (SPORE) submission, under the leadership of PI's Dr. Wong and Dr. Velcheti. Recently, the team lead by Dr. Huang & Dr. Poirier submitted a P01, encompassing a multi-pronged approach in elucidating replication stress-related mechanisms, biomarkers, and unveiling new therapeutic strategies in targeting chemo-sensitive and chemo-resistant SCLC.



MEGAN WINNER, MD



RIMMA BELENKAYA, MA, MS

## Database & PCC Data Hub

The mission of the Perlmutter Cancer Center Data Hub is to integrate and centralize data to support clinical and population science research, with the goal of improving research and patient care. The data hub provides cancer context-specific data and tools that speed and enhance data uses.

Under the leadership of Co-Director Dr. Winner, and Associate Director, Head of Cancer Informatics, Rimma Belenkaya, the PCC Data Hub has assisted with and completed several projects for the LCC, helping us dig into several hypothesis driven research questions. Of note, the PCC Data Hub is focusing on merging our basic science RedCap databases, to allow for continuity of data sets, and enhance research collaboration between investigators and their teams. Additionally, they have worked on several large data queries to answer research questions around senescence, smoking related cancers, genetic reporting, and patient engagement with the NYULH/PCC system.

# CLINICAL TRIAL HIGHLIGHTS: ACTIVE & RECRUITING

## STK11

**s22-01128 (PI: Dr. Punekar):** Phase 1/2, Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an anti-PD-1 Antibody In Patients With STK11 mutated Advanced Solid Tumors **MANHATTAN**

**s22-01512 (PI: Dr. Lau):** Single-Arm Phase 2 Study, Daratumumab in Previously Treated STK11/LKB1 Mutated Non-Small Cell Lung Cancer **MANHATTAN**

## SCLC

**s22-00293 (PI: Dr. Lau):** Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer **MANHATTAN & LONG ISLAND**

## KRAS

**s22-00959 (PI: Dr. Punekar):** Phase 1/2 Study, Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) **MANHATTAN**

## ALK

**s22-01005 (PI: Dr. Lau):** Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1) **MANHATTAN**



# ASCO ANNUAL MEETING HIGHLIGHTS

## Real-World Clinical Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib (Osi) Stratified by EGFR Subtype

Ying Liu, Jason Bi, Andre Moreira, Abraham Chachoua, Vamsidhar Velcheti, Sally C.M. Lau, Salman Rafi Punekar, Joshua K. Sabari, Elaine Shum

The FLAURA trial demonstrated a median PFS (mPFS) of 19 months (mos) and overall survival (OS) of 38.6 mos with osi. Subgroup analysis suggested this survival benefit was not seen in Asian patients (pts) or in pts with the L858R mutation.

We conducted a single institution IRB-approved retrospective study of Asian pts treated at NYU Perlmutter Cancer Center with stage IV NSCLC with EGFR ex19del or L858R mutations treated with osi.

In accordance with the FLAURA data, our real-world analysis revealed that Asian pts treated with 1L osi was comparable to pts treated with 1st- or 2nd- generation TKIs. Furthermore, our data showed that the use of 1L osi had a lower 2y OS in Asian pts with ex19del compared to those pre-treated with TKIs, but this was not the case with L858R. This was a small sample size of patients and further analysis is ongoing.

## Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS)

Elaine Shum, Wenyuan Li, Lecia V. Sequist, Sai-Hong Ignatius Ou, Judith D. Goldberg, Abraham Chachoua, Kwok-Kin Wong

The primary objective of the Female Asian Nonsmoker Screening Study (FANSS) study, is to develop a database of clinical, demographic, and radiographic data of Asian women nonsmokers who undergo LDCT to determine feasibility of lung cancer screening.

Preliminary results from FANSS, demonstrate an invasive lung adenocarcinoma detection rate of 1.5%, which is comparable to TALENT, a large lung cancer screening study conducted in Taiwan for nonsmokers. The FANSS pilot study demonstrates that lung cancer screening for Asian females who do not smoke in the U.S. is feasible.

Continued efforts include enrollment and expansion of FANSS to additional sites across the U.S., starting with MGH & UC Irvine, and analysis of collected plasma-based ctDNA samples as a tool for early detection.

## Large Scale Evaluation of Pulmonary Nodule Workup: A Real-World Study of Over 150,000 Patients in New York State

Vamsidhar Velcheti, Erika Klump, Andrew Long, Hadrian Green, Tessa Williams, Tielman Van Vleck, Hesper Wong, Randall Legg, Jon Apple, Bobby Arelli, Ilker Arslan

Around 1.6 million patients in the US annually have a pulmonary nodule (PN) found on imaging, with PNs  $\geq 6$ mm considered higher risk. Despite guideline availability, only about one-third of commercially insured patients with a PN receive recommended workup.

Using a retrospective cross-sectional design, structured demographic and unstructured clinical data were used to analyze patient documents from a NY state health information exchange from January 2018 to February 2022. 58 million documents from 5.5 million unique patients across 7 NY state healthcare institutions were analyzed. Of the overall 151,436 patients with PNs, workup was found in 47% (71,071).

The descriptive findings of this analysis demonstrate gaps and variations in workup for patients with PNs across different demographics and clinical scenarios. A subsequent project is underway to explore strategies for improvement in adherence to guideline-recommended care, to benefit patients by diagnosing lung cancer at an earlier, potentially curative stage.

	FANSS	NLST	TALENT
<b>Screened population</b>	Asian women who never smoked	Individuals who have smoked at least 30 pack years and if former, quit in previous 15 years	Asian men and women who have smoked and additional risk factor
<b>n</b>	201	26,722	12,011
<b>Positive Screen</b>	Lung-RADS 3 or 4: Solid, part solid nodule $\geq 6$ mm; GGO $\geq 30$ mm	Non-calcified nodule $\geq 4$ mm	Solid nodule $>6$ mm; GGO $>5$ mm
<b>Baseline LDCT Lung Cancer Detection Rate</b>	1.5% (invasive adenocarcinoma)	1.1%	• 2.6% (includes <i>in situ</i> and minimally invasive) • 1.5% (invasive adenocarcinoma)

Shum et al, 2023



SALLY LAU, MD

## Conquer Cancer Career Development Award

Dr. Lau received a 2023 Conquer Cancer Career Development Award, providing three years of research funding for her project titled "Defining the Glutamine-Dependent Mechanisms of Resistance in KRAS and KEAP1 Mutated Non-Small Cell Lung Cancer"

# ANNOUNCEMENTS

## LCC Annual Retreat - October 28, 2023

### MARK YOUR CALENDARS!



**Location:** NYU Langone Health  
Science Building, Ground Floor, G-19  
435 E 30th St, New York, NY 10016

**Time:** 9:00am-3:00pm

**Agenda:** Forthcoming

*If you did not receive an invite for the retreat and you are interested in attending, please reach out so we can forward you the invite and details*

## Medscape Series 'Teamwork: A Multidisciplinary Approach to Early Lung Cancer'



Episode's 1 & 2 of 'Teamwork: A Multidisciplinary Approach to Early Lung Cancer' premiered recently on Medscape video, highlighting the multidisciplinary approach to the treatment of early-stage non-small cell lung cancer as the most effective for optimal patient outcomes. The series, which features our Lung Cancer Center team, explores the evolution of NSCLC care, and how our coordinated efforts as a multidisciplinary team individualize the treatment plan for each of our NSCLC patients. The series features Dr. Sterman, Dr. Chachoua, Dr. Shum, Dr. Cooper, and Dr. Kent.

Check out the first two episodes, streaming now, at: <https://www.medscape.com/mtv/lung-cancer-s07>

## Be Featured in Future LCC Newsletters & Participate in LCC Priority Workgroup Meetings



If you are interested in attending any of our LCC Priority Workgroup meetings, or have an exciting story you'd like featured in future newsletters, please reach out to Kristen Labbe for meeting invites or with details.



**LUNG CANCER CENTER**

MANHATTAN • BROOKLYN • QUEENS • LONG ISLAND